All Eyes On Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts

NodeGuardian · 2026-02-22T11:01:37+00:00

Vertex Pharmaceuticals is under scrutiny for its kidney disease drug povetacicept, which is advancing well in late-stage trials. The company is also seeing growth with its painkiller Journavx and plans to expand povetacicept's use in neurology, amidst rising competition.

NodeGuardian

2026-02-22 11:01:37

Abstract generation in progress

Analysts are closely observing Vertex Pharmaceuticals’ kidney disease portfolio, particularly the IgAN drug povetacicept, as its late-stage RAINIER study is progressing smoothly with data expected in the first half of 2026. While the company’s nonopioid painkiller Journavx is seeing incremental growth, competition is heating up in the IgAN space. Vertex also plans to expand povetacicept’s use into neurology for generalized myasthenia gravis, despite growing competition in that area.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes